

analgesic for outpatient procedures. *Br J Anaesth* 2018; **120**: 1040–8

3. Cousins MJ, Mazze RI. Methoxyflurane nephrotoxicity: a study of dose response in man. *JAMA* 1973; **225**: 1611–6
4. Frangos J, Mikkonen A, Down C. Derivation of an occupational exposure limit for an inhalation analgesic methoxyflurane (Penthrox). *Regul Toxicol Pharmacol* 2016; **80**: 210–25

doi: 10.1016/j.bja.2018.03.004

Advance Access Publication Date: 13 April 2018

© 2018 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

## Safety of subsequent general anaesthesia in patients allergic to neuromuscular blocking agents: value of allergy skin testing

A. M. Chiriac<sup>1,2</sup>, C. Tacquard<sup>3</sup>, N. B. Fadhel<sup>1</sup>, C. Pellerin<sup>4</sup>, J. M. Malinovsky<sup>5</sup>, P. M. Mertes<sup>3,\*</sup> and P. Demoly<sup>1,2</sup>

<sup>1</sup>Montpellier, France, <sup>2</sup>Paris, France, <sup>3</sup>Strasbourg, France, <sup>4</sup>Bordeaux, France and <sup>5</sup>Reims, France

\*Corresponding author E-mail: [paul-michel.mertes@chru-strasbourg.fr](mailto:paul-michel.mertes@chru-strasbourg.fr)

Editor—Allergy to neuromuscular blocking agents (NMBA) is the leading cause of perioperative anaphylaxis in France. In the last GERAP survey (*Groupe d'Etude des Réactions Anaphylactiques Peropératoires*), proved NMBA allergy accounted for 60.6% of the immediate hypersensitivity reactions in the perioperative setting (302 patients explored between 2011 and 2012).<sup>1</sup>

Immunoglobulin E-mediated reactions to NMBAs have also been reported with a high frequency in other parts of Europe (UK, Norway, Belgium, and Spain) and in Australia and New Zealand.<sup>2</sup>

When confronted with patients allergic to NMBA, anaesthetists are bound to avoid all NMBAs. It is generally accepted




Fig 1. Flow chart of the study. NMBA, neuromuscular blocking agent; ST, skin test.

**Table 1** Characteristics of the 25 patients with subsequent neuromuscular blocking agent administration. F, female; M, male; mo, months; NA, not available; ND, not done; NMBA, neuromuscular blocking agent; GA, general anaesthesia; ST, skin test; A, atracurium; C, cis-atracurium; Miv, mivacurium; P, pancuronium; R, rocuronium; S, suxamethonium; V, vecuronium; SPT, skin prick test at maximum allowed concentration (see [Supplementary Table 1](#)), unless otherwise specified; IDT, intradermal test. <sup>†</sup>Patient 3: Cis-atracurium was injected at the end of the intervention and later on proved to be negative in skin tests. <sup>‡</sup>Patients 5 and 11 had reactions to subsequent GA (full description in text). <sup>§</sup>Patients 18 and 24 had two allergy evaluations by skin testing, a few years apart. Patient 24 had positive prick test to suxamethonium upon the first and second evaluation, 19 yr apart. <sup>¶</sup>Patients 19 and 21 had two uneventful subsequent GA

| Patient number  | Sex | Age at index reaction (yr) | Type of surgery/exam       | Severity of index reaction | Injected NMBA | Serum tryptase during index reaction ( $\mu\text{g litre}^{-1}$ ) | Delay reaction-ST (mo) | Positive ST                | Negative ST        | Delay ST-next GA (mo) | Type of surgery/exam                                                             | Re-injected NMBA | Indication |
|-----------------|-----|----------------------------|----------------------------|----------------------------|---------------|-------------------------------------------------------------------|------------------------|----------------------------|--------------------|-----------------------|----------------------------------------------------------------------------------|------------------|------------|
| 1               | F   | 43                         | Head trauma                | III                        | S             | ND                                                                | 8                      | S <sup>SPT</sup>           | Miv, A, C, V, R    | 1                     | Cranioplasty                                                                     | R                |            |
| 2               | F   | 34                         | NA                         | III                        | S             | 36.1                                                              | 3                      | S <sup>SPT</sup>           | Miv, A, C, V, R    | 2                     | Laparoscopy                                                                      | C                | Yes        |
| 3 <sup>†</sup>  | M   | 40                         | Cholecystectomy            | IV                         | S             | ND                                                                | NA                     | S <sup>SPT</sup> , C, V, R | Miv, A             | 0                     | Cholecystectomy                                                                  | A                | Yes        |
| 4               | F   | 57                         | Osteosynthesis (ankle)     | IV                         | S             | ND                                                                | 72                     | S <sup>IDT 10-3</sup>      | Miv, A, C, V, R, P | 1                     | Thyroidectomy                                                                    | C                |            |
| 5 <sup>†</sup>  | F   | 53                         | Laparoscopy (ovarian cyst) | IV                         | S             | ND                                                                | 2                      | S <sup>SPT</sup> , V       | Miv, A, C, R, P    | 8                     | Laparoscopy (ovarian cyst)                                                       | R                | Yes        |
| 6               | M   | 68                         | NA                         | NA                         | R             | ND                                                                | NA                     | R <sup>SPT</sup> , S       | Miv, A, C          | 2                     | Sigma resection                                                                  | C                | Yes        |
| 7               | F   | 52                         | NA                         | NA                         | S             | ND                                                                | 372                    | S <sup>SPT</sup>           | Miv, A, C, V, R    | 1                     | Right transtibial amputation                                                     | C                |            |
| 8               | M   | 34                         | NA                         | III                        | S             | ND                                                                | 3                      | S <sup>IDT 10-3</sup>      | A, C, R            | <21                   | Herniated lumbar disc                                                            | A                | Yes        |
| 9               | F   | 44                         | NA                         | III                        | R             | ND                                                                | 228                    | R <sup>SPT</sup> , V, P    | A, C, S            | 24                    | Sigma resection                                                                  | A                | Yes        |
| 10              | F   | 45                         | NA                         | II                         | S             | 76                                                                | 1                      | S <sup>SPT</sup>           | Miv, A, C, V, R    | <21                   | Herniated lumbar disc                                                            | A                | Yes        |
| 11 <sup>†</sup> | F   | 56                         | NA                         | III                        | S             | 30                                                                | 3                      | S <sup>SPT</sup>           | A, C, R            | 2                     | Sleeve gastrectomy                                                               | R, C             | Yes        |
| 12              | M   | 66                         | NA                         | III                        | A             | 292                                                               | 3                      | A <sup>IDT 10-3</sup> , C  | Miv, S, V, R       | <36                   | Cholecystectomy                                                                  | V                | Yes        |
| 13              | F   | 57                         | Recto-vesicular fistula    | III                        | S             | 149                                                               | 1                      | S <sup>IDT 1/500</sup>     | C, R               | 13                    | Gastric ring removal                                                             | C                | Yes        |
| 14              | M   | 70                         | Colonoscopy                | III                        | S             | 104                                                               | 2                      | S <sup>SPT</sup>           | C, R               | 4                     | Rectal resection                                                                 | C                | Yes        |
| 15              | F   | 37                         | Sleeve gastrectomy         | III                        | S             | 6.2                                                               | 1                      | S <sup>SPT</sup>           | A, R               | 1                     | Sleeve gastrectomy                                                               | A                | Yes        |
| 16              | F   | 15                         | Nose trauma                | III                        | S             | ND                                                                | 408                    | S <sup>SPT</sup> , V, R    | A, C               | 4                     | Sleeve gastrectomy                                                               | C                | Yes        |
| 17              | F   | 57                         | Tricuspid valve repair     | IV                         | S             | 233                                                               | 9                      | S <sup>SPT</sup>           | A, C, R            | 1                     | Mitral valve replacement                                                         | C                | Yes        |
| 18 <sup>‡</sup> | M   | 70                         | Pubic bone biopsy          | III                        | S             | >200                                                              | 1 and 48               | S <sup>SPT 10-1</sup>      | Miv, A, C, V, R    | 1                     | Cholecystectomy                                                                  | C                | Yes        |
| 19 <sup>¶</sup> | M   | 49                         | Gastric by-pass            | III                        | A             | >200                                                              | 4                      | A <sup>SPT</sup>           | S, R               | 21                    | Gastroscopy                                                                      | S                | Yes        |
| 20              | M   | 61                         | Cholecystectomy            | I                          | S             | ND                                                                | NA                     | S <sup>IDT 1/500</sup>     | Miv, A, C, R       | NA                    | Laparotomy                                                                       | R                |            |
| 21 <sup>¶</sup> | F   | 57                         | Foreign body extraction    | IV                         | S             | ND                                                                | NA                     | S <sup>SPT</sup> , A       | C, R               | <36<br><48            | Abdominal incisional hernia<br>Total hysterectomy<br>Abdominal incisional hernia | C<br>C<br>C      | Yes        |
| 22              | M   | 44                         | Vertebral collapse         | III                        | S             | 20                                                                | NA                     | S <sup>IDT 1/500</sup>     | Miv, A, C, V, R    | <24                   | Vertebral collapse                                                               | C                | Yes        |
| 23              | F   | 18                         | Appendectomy               | III                        | S             | ND                                                                | NA                     | S <sup>SPT</sup> , V       | A                  | NA                    | Retroperitoneal coelioscopy                                                      | A                | Yes        |
| 24 <sup>‡</sup> | F   | 39                         | Caesarean                  | III                        | S             | ND                                                                | 36 and 228             | S <sup>SPT</sup> , R       | Miv, A, C          | 1                     | Sigma resection                                                                  | C                | Yes        |
| 25              | M   | 58                         | Hip replacement            | III                        | R             | ND                                                                | 204                    | R <sup>SPT</sup> , S       | Miv, A, C          | 2                     | Abdominal aortic aneurysm                                                        | C                | Yes        |

that allergy skin testing is the method of choice to identify the culprit NMBA, possible cross-reactivities with other NMBAs and potential safe alternatives.<sup>3</sup> However, only a few reports (biased by small numbers of included patients) have tackled the issue of the negative predictive value (NPV) of NMBA skin testing in patients allergic to at least one NMBA.<sup>4–9</sup> As control trials are not realistic, follow-up surveys in real life should assess tolerance of a negative skin tested NMBA in subsequent general anaesthesia. Although the NPV is high in most reports, reactions to negative skin tested NMBAs have been reported.<sup>5–7</sup>

Between 2011 and 2016, a multicentre follow-up survey of NMBA allergic patients was conducted in four centres in France (Bordeaux, Montpellier, Strasbourg, and Reims). All diagnostic procedures for NMBA allergy followed the recommendations of the *Société Française d'Anesthésie Réanimation*, endorsed by the Drug Allergy Interest Group/European Network of Drug Allergy of the European Academy of Allergy and Clinical Immunology.<sup>3</sup> The diagnosis of allergy to NMBA was based on a compatible clinical history, positive skin test, and exclusion of other potential allergens. When allergy to an NMBA was diagnosed, cross-reactivity was assessed to other NMBAs. Initial reactions (referred to as index reactions) were graded according to severity (Supplementary Fig. 1).<sup>1</sup> Patients with positive skin testing to at least one NMBA were contacted and questioned about subsequent general anaesthesia. All patients included in this study gave their consent to participate in the survey, and to have the records of their subsequent general anaesthesia exposures retrieved and analysed. The study received approval from local Ethics Committees.

Of the 148 patients allergic to NMBA, 118 were successfully contacted (rate of response, 79.7%). Of the 92 patients undergoing a subsequent general anaesthetic procedure, only 25 (27.2%) received another NMBA (Fig. 1). The characteristics of these 25 patients are presented in Table 1. Female patients were predominant (15 patients, 60%). Mean age was 47.9 yr (range, 15–70) and half were tested within 4 months after the index reaction (inter-quartile range Q25–75:2–204). Most index reactions (84%) were severe, life-threatening events (16 Grade III and five Grade IV reactions), and positivity for the culprit agent occurred in skin prick testing in 19 patients (76%). In 100% of patients, the NMBA responsible for the index reaction was skin test positive: suxamethonium in 20 patients (80%), rocuronium and atracurium in three (12%) and two (8%) patients, respectively. Cross-reactivity was systematically assessed (with three to seven NMBA tested/patient), and was found in 10 patients (40% of patients). The most frequently re-injected NMBA was cis-atracurium (16 administrations in 15 patients, 60%), followed by atracurium (five patients, 24%) and rocuronium (four patients, 16%).

Two patients (8%, Patients 5 and 11, Table 1) reacted with anaphylaxis upon re-exposure to a negative skin tested NMBA. Patient 5 underwent a new general anaesthesia within 2 months after the initial allergy work-up that had proved allergic to suxamethonium (with cross-reactivity to vecuronium, but not to rocuronium). She received rocuronium and reacted with generalised cutaneous erythema, hypotension (75/35 mm Hg), and tachycardia. Tryptase during the reaction was 5.1 µg litre<sup>-1</sup> (basal tryptase not measured). The reaction was antagonised with ephedrine, methylprednisolone, and dexchlorpheniramine. Upon the second evaluation (performed 9 months after the second reaction), she exhibited positive skin testing to rocuronium and was considered allergic to this NMBA. The reaction presented by Patient 11 was interpreted as probable non-specific histamine-release. This patient reacted

with severe bronchospasm, followed by cardiovascular collapse, after administration of two negative skin tested NMBAs, rocuronium and cis-atracurium. The reaction was antagonised with salbutamol, ephedrine, and i.v. fluids. The tryptase (perioperative at 30 min and 1 h after the episode: 5.7 µg litre<sup>-1</sup> and 2.5 µg litre<sup>-1</sup>, respectively, with baseline 4.8 µg litre<sup>-1</sup>) did not support an allergic aetiology. Subsequent evaluation indicated underlying bronchial hyperreactivity and negative drug allergy evaluation for all involved drugs.

The NPV of skin tests to NMBA in our study is 96% (95% confidence interval: 88.3–99.9%) when considering only one reactor. These results confirm previous findings regarding the value of skin testing in NMBA allergy.<sup>4–6,8,9</sup> The high NPV in our series could also be related to preferential use (60%) of cis-atracurium for subsequent general anaesthesia procedures. Recently, Tacquard and colleagues<sup>1</sup> showed a lower estimated risk of cis-atracurium-related allergic reactions, compared with both suxamethonium and rocuronium, when their respective market share is taken into account (0.4/100 000 vials compared with 13.8 and 13.3/100 000 vials, respectively). Most of the patients presented in this survey suffered from severe life-threatening index reactions, in accordance with literature data on NMBA allergy; all the more reason for these results to be valuable.

Like others,<sup>5–7</sup> we have found that in a minority of patients, allergic reactions can occur despite initial negative skin testing. Two hypotheses arise: false negative skin tests at first evaluation or re-sensitisation. Neither can be confirmed or ruled out. Therefore, vigilance is mandatory and strict indications of NMBA usage in an NMBA allergic patient should be followed. Validation of negative skin testing for NMBA by a drug provocation test, which is considered to be the 'gold standard allergy test' for most drugs, is not considered as such for NMBA because of the pharmacological effects of these drugs and the unfavourable risk-benefit ratio for conducting such tests.<sup>3</sup> In order to evaluate tolerance of a therapeutic dose of a negative skin test NMBA, a full therapeutic dose should be administered, and this cannot occur in the absence of general anaesthesia. Whether or not provocation tests to NMBA can be performed within a clear frame established by research studies remains to be discussed.

Cross-reactivity might have been underestimated in our study, because all commercially available NMBA were not systematically tested, either because of retirement from the French market (e.g. pancuronium) or low use in daily clinical practice (e.g. vecuronium, mivacurium). However, estimation of cross-reactivity was not the purpose of this paper.

Current strategies to reduce overall mortality and morbidity of perioperative anaphylaxis rely on the knowledge and vigilance of the attending clinicians. This survey sums up to present (scarce) knowledge regarding the safety of negative skin tested NMBAs in NMBA-allergic patients.

## Authors' contributions

Patient recruitment: A.M.C., C.T.

Data collection and analysis: A.M.C., C.T., N.B.F., C.P.

Writing up the first draft of the paper: A.M.C., C.T.

Revising the manuscript: N.B.F., C.P., J.M.M., P.M.M., P.D.

Study design, data interpretation: J.M.M., P.M.M., P.D.

## Declaration of interest

J.M.M., P.M.M., C.P., and P.D. are investigators in the ALPHO study (No IDRCB Alphi: 2012-A01735-38) which assesses the link between pholcodine exposure and NMBA allergy. This

study is sponsored by an industrial consortium (Zambon, Urgo, Boots, Pierre Fabre, Hepatoum, Biocodex, Sanofi, Bouchara-Recordati, Gsk, Apl, Bells Healthcare, Pinewood, Thornton & Ross Ltd, Ernest Jackson).

## Acknowledgements

We thank M.C.B. Boyer for revising the manuscript, and our clinical research technician, L. Ferrando for the help provided throughout the study.

## Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.idh.2018.02.006>.

## References

1. Tacquard C, Collange O, Gomis P, et al. Anaesthetic hypersensitivity reactions in France between 2011 and 2012: the 10th GERAP epidemiologic survey. *Acta Anaesthesiol Scand* 2017; **61**: 290–9
2. Mertes PM, Volcheck GW, Garvey LH, et al. Epidemiology of perioperative anaphylaxis. *Presse Med* 2016; **45**: 758–67
3. Mertes PM, Malinovsky JM, Jouffroy L, et al. Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice. *J Investig Allergol Clin Immunol* 2011; **21**: 442–53
4. Leynadier F, Calinaux C, Dry J. Predictive value of intradermal tests using muscle-relaxing drugs. *Ann Fr Anesth Reanim* 1989; **8**: 98–101
5. Fisher MM, Merefield D, Baldo B. Failure to prevent an anaphylactic reaction to a second neuromuscular blocking drug during anaesthesia. *Br J Anaesth* 1999; **82**: 770–3
6. Thacker MA, Davis FM. Subsequent general anaesthesia in patients with a history of previous anaphylactoid/anaphylactic reaction to muscle relaxant. *Anaesth Intensive Care* 1999; **27**: 190–3
7. Fraser BA, Smart JA. Anaphylaxis to cisatracurium following negative skin testing. *Anaesth Intensive Care* 2005; **33**: 816–9
8. Ramirez LF, Pereira A, Chiriac AM, Bonnet-Boyer MC, Demoly P. Negative predictive value of skin tests to neuromuscular blocking agents. *Allergy* 2011; **67**: 439–41
9. Leysen J, Uyttendaele A, Sabato V, Bridts CH, De Clerck LS, Ebo DG. Predictive value of allergy tests for neuromuscular blocking agents: tackling an unmet need. *Clin Exp Allergy* 2014; **44**: 1069–75

doi: 10.1016/j.bja.2018.03.004

Advance Access Publication Date: 13 April 2018

© 2018 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

# Alfaxalone and comments on: Thiopental to desflurane—an anaesthetic journey. Where are we going next? [Br J Anaesth 2017;119:i44–52]

J. Serrao\* and C. Goodchild

Malvern, Victoria, Australia

\*Corresponding author. E-mail: [juliet@drawbridgepharmaceuticals.com.au](mailto:juliet@drawbridgepharmaceuticals.com.au)

Editor—In his comment<sup>1</sup> related to his recent review article,<sup>2</sup> Sneyd suggests that introduction into clinical practice of a new formulation of alfaxalone 10 mg ml<sup>-1</sup> dissolved in water using 13% sulfobutyl ether  $\beta$  cyclodextrin (SBECD) (Phaxan™) for i.v. anaesthesia and sedation, may be impeded by two key issues: toxicity of SBECD and lack of economic or clinical advantage of the greater cardiovascular stability afforded by alfaxalone anaesthesia compared with propofol. We believe these arguments, as presented, are flawed.

In discussing his calculations of SBECD doses involved with intensive care sedation, Sneyd says ‘Clinicians often administer medicines outwith their licensed doses and indications so considering the extremes is appropriate’. This argument is fallacious. If not, then one would say that propofol is an unsuitable agent because of lipid toxicity syndrome.<sup>3</sup> Considering the administration of alfaxalone formulated in SBECD, Sneyd referred to Ramsay and colleagues,<sup>4</sup> who reported the doses of Althesin (the previous formulation of alfaxalone) used to sedate patients in their

intensive care unit. In calculating the possible toxic load of SBECD, Sneyd made use of the fact that the SBECD formulation of alfaxalone is equipotent with Althesin<sup>5,6</sup>; one would expect the same dose in millilitres per hour of alfaxalone-SBECD would be used instead of Althesin to achieve the same level of sedation. Sneyd cites the most extreme case of Althesin 4367 ml administered to one patient which, if changed to alfaxalone-SBECD, would result in an overall dose of 10 322 mg kg<sup>-1</sup> SBECD. He goes on to say ‘renal and hepatic toxicities have been described in rats<sup>6</sup> receiving sulfobutyl ether beta cyclodextrin 3000 mg kg<sup>-1</sup>, albeit over a shorter period’.<sup>1</sup> This argument is specious. First, the patient in question weighed 55 kg and received that dose of SBECD over 14 days, or 737 mg kg<sup>-1</sup> day<sup>-1</sup> SBECD. The daily safe dose of SBECD as reported by Luke and colleagues<sup>7</sup> is 1500 mg kg<sup>-1</sup> day<sup>-1</sup>, and fully reversible renal and hepatic histological changes occurred after 3000 mg kg<sup>-1</sup> day<sup>-1</sup> SBECD given daily for 1 month, not for a shorter period as stated by Sneyd.<sup>1</sup> Furthermore, Stella and He<sup>8</sup> point out that the vacuolation

| Severity grade | Symptoms                                                                                                                                        |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| I              | Cutaneous signs: erythema, urticaria with or without angioedema                                                                                 |
| II             | Presence of measurable but no life-threatening symptoms: cutaneous effects, arterial hypotension, cough or difficulty in mechanical ventilation |
| III            | Presence of life-threatening reactions: cardiovascular collapse, tachycardia or bradycardia, arrhythmias, severe bronchospasm                   |
| IV             | Circulatory failure, cardiac and/or respiratory arrest                                                                                          |

**Table 2** Skin test concentrations used in the 25 patients, according to Mertes and colleagues<sup>3</sup>

| Neuro-muscular blocking agent | Commercial vial (mg ml <sup>-1</sup> ) | Skin prick test (maximum allowed concentration) | Intradermal test |
|-------------------------------|----------------------------------------|-------------------------------------------------|------------------|
| Atracurium                    | 10                                     | 10-1                                            | 10-3             |
| Cis-atracurium                | 2                                      | Undiluted                                       | 10-2             |
| Mivacurium                    | 2                                      | 10-1                                            | 10-3             |
| Pancuronium                   | 2                                      | Undiluted                                       | 10-1             |
| Rocuronium                    | 10                                     | Undiluted                                       | 1/200            |
| Suxamethonium                 | 50                                     | 1/5                                             | 1/500            |
| Vecuronium                    | 4                                      | Undiluted                                       | 10-1             |